Effects of risedronate on fracture risk in postmenopausal women with osteopenia

SUMMARY: This posthoc analysis of four trials studied the efficacy of risedronate to reduce fragility fractures in postmenopausal women with osteopenia (i.e., T-scores between −1 and −2.5). Risedronate reduced the fracture risk by 73% ( = 0.023) in this population of women with low femoral neck bone...

Descripción completa

Detalles Bibliográficos
Autores principales: Siris, E. S., Simon, J. A., Barton, I. P., McClung, M. R., Grauer, A.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2007
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2277453/
https://www.ncbi.nlm.nih.gov/pubmed/17968610
http://dx.doi.org/10.1007/s00198-007-0493-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2277453/
https://www.ncbi.nlm.nih.gov/pubmed/17968610
http://dx.doi.org/10.1007/s00198-007-0493-y

Ejemplares similares